News

March 2, 2021

TGA collecting COVID-19 vaccine side effect reports

March 1, 2021

ATAGI COVID-19 vaccination decision guide for frail older people, including those in residential aged care facilities

March 1, 2021

New immunisation reference page: Immunisation recommendations for the older population

March 1, 2021

ATAGI COVID-19 vaccination decision guide for women who are pregnant, breastfeeding or planning pregnancy

March 1, 2021

Effectiveness of First Dose of COVID-19 Vaccines Against Hospital Admissions in Scotland

February 25, 2021

The University of Melbourne: Learning as we go during vaccine rollout

February 25, 2021

The Conversation: When vaccinating 26 million Australians, expect a mistake or two. But we can minimise the risk of repeating Queensland’s overdose incident

February 23, 2021

New immunisation reference page: Pneumococcal disease and vaccines

February 18, 2021

Registrations now open for the March CVU miniseries event

February 16, 2021

A recording of the February CVU mini is now available

February 16, 2021

Victorian COVID-19 e-Learning Competency

February 16, 2021

TGA provisionally approves AstraZeneca’s COVID-19 vaccine

February 15, 2021

COVID-19 Vaccination Intent, Perceptions, and Reasons for Not Vaccinating Among Groups Prioritized for Early Vaccination

February 15, 2021

Patterns of COVID-19 dynamics following deployment of a broad national immunization program

February 14, 2021

COVID vaccine offers two-thirds protection in just one jab

February 11, 2021

New immunisation reference page: Multi-dose vials

February 11, 2021

Building a stronger Australian Immunisation Register

February 10, 2021

Imperial College London survey suggests confidence in coronavirus vaccines is rising globally

In the final episode of this podcast series our host, Associate Professor Nigel Crawford, speaks with Professor Walter Orenstein. Dr Orenstein is a Professor of Medicine, Epidemiology, Global Health and Paediatrics at Emory University; Associate Director of the Emory Vaccine Center and the Director of Emory Vaccine Policy and Development. An expert in vaccinology, Dr Orenstein has worked at the US Centers for Disease Control and Prevention, Director of the United States Immunisation Program and is a current member of several WHO groups. Further to this he is the co-editor of the vaccine textbook, Plotkin’s Vaccines, 7th edition. In this episode they discuss:

•Lessons that can be learnt from Plotkin’s Vaccines in the setting of the SARS-CoV-2 pandemic and development of vaccines
•Recent press releases showing promising early results from two mRNA COVID-19 vaccine candidates developed by Pfizer/BioNTech and Moderna
•The critical role of ongoing monitoring for safety and effectiveness of vaccines once they are in use
•The likely highest priority groups when vaccines do become available
•The role of children in SARS-CoV-2 transmission and whether or not they need to be vaccinated
•The importance of a correlate of protection in SARS-CoV-2 vaccines
•The need to monitor for vaccine associated enhanced disease (VAED)
•The importance of immunisation providers supporting reports of adverse events following immunisation (AEFI)
•The importance of communication in supporting vaccine acceptance and uptake
•Key next steps on the road to a COVID-19 vaccine: a better understanding of how many doses are required and when, a prioritisation process so the vaccines can be used most effectively (with a clear allocation system); and communicating to the public that social distancing and wearing a mask will be ongoing for some time as a level of normality won’t be reached immediately, even with the exciting new efficacious COVID-19 vaccines

Links:

Plotkin’s Vaccines, 7th ed
https://www.elsevier.com/books/T/A/9780323357616

Pfizer/BioNTech conclude phase 3 study of COVID-19 vaccine candidate, meeting all primary efficacy endpoints
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine

Moderna’s COVID-19 vaccine candidate meets its primary efficacy endpoint in the first interim analysis of the phase 3 COVE study
https://investors.modernatx.com/news-releases/news-release-details/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacy

The final episode of COVID19 Road to a vaccine with Professor Walter Orenstein

Episode play icon

The final episode of COVID19 Road to a vaccine with Professor Walter Orenstein

November 23, 2020

MVEC

Episode play icon

How the COVID-19 pandemic is being managed in British Columbia, Canada, with Dr Bonnie Henry

November 16, 2020

MVEC

Search Results placeholder